Hatsue Fujino

13PUBLICATIONS
35CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyHaematological tumoursMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 16, 2026
Trends in the Proportion of Hepatitis C Virus Antibody-Positive Patients Who Could be Considered for Direct-Acting Antiviral Therapy Identified Through Preoperative Testing for Ophthalmic Surgery: A Nationwide Multicenter Real-World Cohort Study in Japan.

|May 04, 2026
Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.

|May 04, 2026
A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

|Feb 07, 2026
Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda

|Oct 29, 2025
Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients.

Keiichi Hiraoka, Masataka Tsuge, Michihiko Kawahara

|Jan 22, 2025
Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B.

Masanari Kosaka, Hatsue Fujino, Masataka Tsuge

Pageof 3

Frequent Collaborators

10 joint publications

Atsushi Ono

6 joint publications

Shinsuke Uchikawa

6 joint publications

Eisuke Murakami

6 joint publications

Masataka Tsuge